THP	B-Chemical
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
reducing	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
and	O
reducing	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
in	O
mice	O
.	O

Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O

Differential	O
effects	O
of	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
lindane	B-Chemical
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B-Disease
.	O

Pneumonitis	O
with	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusion	I-Disease
and	O
neuropathy	B-Disease
during	O
amiodarone	B-Chemical
therapy	O
.	O

A	O
deficient	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
-	O
nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	O
in	O
cortisol	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	B-Chemical
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
clones	O
.	O

Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O

Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B-Disease
,	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
,	O
VPA	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
and	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O

Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	B-Chemical
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Chemical
vasopressin	I-Chemical
nor	O
oxytocin	B-Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	B-Chemical
(	O
epinephrine	B-Chemical
)	O
,	O
atropine	B-Chemical
and	O
furosemide	B-Chemical
was	O
successful	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B-Disease
are	O
briefly	O
discussed	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
treatment	O
with	O
CC	B-Chemical
.	O

Terbutaline	B-Chemical
,	O
a	O
beta2	O
-	O
adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B-Disease
labor	I-Disease
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B-Disease
in	O
dizygotic	O
twins	O
.	O

Five	O
patients	O
with	O
carcinoma	B-Disease
developed	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
characterized	O
by	O
renal	B-Disease
insufficiency	I-Disease
,	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
usually	O
thrombocytopenia	B-Disease
)	O
after	O
treatment	O
with	O
cisplatin	B-Chemical
,	O
bleomycin	B-Chemical
,	O
and	O
a	O
vinca	B-Chemical
alkaloid	I-Chemical
.	O

Ten	O
patients	O
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	B-Chemical
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O

The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	B-Chemical
139317	I-Chemical
on	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
was	O
studied	O
.	O

This	O
CAB	O
-	O
induced	O
anemia	B-Disease
was	O
normochromic	O
and	O
normocytic	O
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	B-Chemical
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B-Disease
-	O
associated	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B-Disease
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O

Beyond	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O

A	O
frequency	O
of	O
bradycardia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	B-Chemical
.	O

In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	B-Chemical
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B-Disease
.	O

CONCLUSIONS	O
:	O
Prilocaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidocaine	B-Chemical
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B-Disease
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Threo	I-Chemical
-	I-Chemical
dihydroxyphenylserine	I-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease
.	O

Intravenous	O
hydration	O
and	O
mannitol	B-Chemical
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-Chemical
.	O

Lamivudine	B-Chemical
for	O
the	O
prevention	O
of	O
hepatitis	B-Disease
B	I-Disease
virus	O
reactivation	O
in	O
hepatitis	B-Chemical
-	I-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBSAG	B-Chemical
)	O
seropositive	O
cancer	B-Disease
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O

Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

INTRODUCTION	O
:	O
Confusion	B-Disease
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

RESULTS	O
:	O
CsA	B-Chemical
,	O
FK506	B-Chemical
and	O
SRL	B-Chemical
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O

RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mitral	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	B-Disease
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O

In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	B-Chemical
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	B-Chemical
.	O

A	O
series	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenoxyacetamide	I-Chemical
adenosine	B-Chemical
A	O
(	O
2A	O
)	O
antagonists	O
is	O
described	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	B-Chemical
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
glomerulosclerosis	B-Disease
(	O
days	O
45	O
-	O
126	O
)	O
.	O

In	O
one	O
infant	O
,	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O

Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	B-Disease
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	B-Disease
injury	I-Disease
(	O
secondary	B-Disease
hyperalgesia	I-Disease
)	O
.	O

The	O
development	O
of	O
ESRD	B-Disease
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	B-Chemical
and	O
furosemide	B-Chemical
.	O

The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	B-Chemical
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B-Disease
overdose	I-Disease
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	B-Disease
,	I-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
and	O
ascending	O
paralysis	B-Disease
.	O

Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	B-Chemical
enhanced	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
had	O
no	O
effect	O
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O

Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
both	O
treated	O
and	O
untreated	O
rats	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
infection	I-Disease
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	B-Chemical
effects	O
in	O
mice	O
.	O

It	O
is	O
concluded	O
that	O
patients	O
on	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B-Disease
pain	I-Disease
or	O
tachyarrhythmia	B-Disease
is	O
observed	O
.	O

These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
is	O
not	O
related	O
to	O
the	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	B-Disease
atrophy	I-Disease
with	O
optic	B-Disease
atrophy	I-Disease
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

E2	B-Chemical
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

Primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	B-Chemical
suppressant	I-Chemical
drugs	O
.	O

The	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
prescribed	O
cyproterone	B-Chemical
acetate	I-Chemical
in	O
combination	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	B-Chemical
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HBeAg	B-Chemical
negativity	O
.	O

BACKGROUND	O
:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	B-Chemical
in	O
heart	B-Disease
failure	I-Disease
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	B-Disease
(	O
2	O
%	O
)	O
and	O
renal	B-Disease
insufficiency	I-Disease
(	O
0	O
%	O
)	O
.	O

Only	O
1	O
prolactinoma	B-Disease
was	O
discovered	O
.	O

Ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	B-Disease
was	O
not	O
.	O

Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	B-Chemical
-	O
associated	O
mental	O
confusion	B-Disease
.	O

Vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
in	O
dairy	O
cows	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	B-Chemical
significantly	O
increased	O
creatinine	B-Chemical
and	O
urea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-Chemical
group	O
)	O
The	O
GM	B-Chemical
-	O
induced	O
proximal	O
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	B-Chemical
together	O
with	O
gum	B-Chemical
Arabic	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
cellulose	O
.	O

The	O
effect	O
of	O
amiloride	B-Chemical
on	O
lithium	B-Chemical
-	O
induced	O
polydipsia	B-Disease
and	O
polyuria	B-Disease
and	O
on	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	B-Chemical
.	O

While	O
the	O
involvement	O
of	O
metronidazole	B-Chemical
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	B-Chemical
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
.	O

In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper	O
-	O
reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O

We	O
suggest	O
that	O
our	O
patient	O
'	O
s	O
tubular	B-Disease
dysfunction	I-Disease
and	O
myopathy	B-Disease
may	O
have	O
resulted	O
from	O
mitochondrial	B-Disease
dysfunction	I-Disease
which	O
is	O
triggered	O
by	O
tacrolimus	B-Chemical
and	O
augmented	O
by	O
lamivudine	B-Chemical
.	O

Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied	O
:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	B-Chemical
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	B-Chemical
0	O
.	O
5	O
%	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	B-Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B-Disease
behaviours	O
.	O

The	O
serum	O
magnesium	B-Chemical
concentration	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	B-Disease
associated	O
with	O
antidepressants	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B-Disease
depression	I-Disease
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putaminal	B-Disease
hemorrhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

The	O
leading	O
causes	O
of	O
death	B-Disease
were	O
pneumonia	B-Disease
and	O
bronchitis	B-Disease
(	O
44	O
.	O
1	O
%	O
)	O
,	O
malignant	O
neoplasms	B-Disease
(	O
11	O
.	O
6	O
%	O
)	O
,	O
heart	B-Disease
diseases	I-Disease
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerebral	B-Disease
infarction	I-Disease
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicaemia	B-Disease
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Three	O
patients	O
developed	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
and	O
LR132	B-Chemical
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O

In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
-	I-Disease
insipidus	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	B-Chemical
level	O
.	O

Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Triamterene	B-Chemical
nephrolithiasis	B-Disease
complicating	O
dyazide	B-Chemical
therapy	O
.	O

She	O
was	O
treated	O
with	O
heparin	B-Chemical
,	O
dipyridamole	B-Chemical
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	B-Disease
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O

Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	B-Chemical
.	O

Differential	O
modulation	O
by	O
estrogen	B-Chemical
of	O
alpha2	O
-	O
adrenergic	O
and	O
I1	O
-	O
imidazoline	B-Chemical
receptor	O
-	O
mediated	O
hypotension	B-Disease
in	O
female	O
rats	O
.	O

Cardioprotective	O
effect	O
of	O
tincture	B-Chemical
of	I-Chemical
Crataegus	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O

Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-Disease
.	O

Climbing	O
behavior	O
induced	O
by	O
apomorphine	B-Chemical
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	B-Chemical
.	O

In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-Disease
mellitus	I-Disease
,	O
use	O
of	O
N	B-Chemical
-	I-Chemical
acetylcysteine	I-Chemical
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O

Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	B-Chemical
did	O
not	O
predict	O
CHF	B-Disease
development	O
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	B-Chemical
-	O
induced	O
anemia	B-Disease
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Laboratory	O
evaluation	O
revealed	O
66	O
,	O
680	O
U	O
/	O
L	O
creatine	B-Chemical
kinase	O
,	O
93	O
mg	O
/	O
dL	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatinine	B-Chemical
,	O
1579	O
U	O
/	O
L	O
aspartate	B-Chemical
aminotransferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanine	B-Chemical
aminotransferase	O
.	O

No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-Disease
hemorrhage	I-Disease
occurred	O
in	O
all	O
nicotine	B-Chemical
sulfate	O
-	O
treated	O
chicks	O
.	O

Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	B-Disease
,	O
proteinuria	B-Disease
,	O
aminoaciduria	B-Disease
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	B-Chemical
clearance	O
,	O
phosphate	B-Chemical
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O

